Actavis is Icelandic for generic. Iceland-based Actavis Group is one of the world's largest generic pharmaceuticals producers. Actavis company has about 350 drugs in its development pipeline, and nearly 1,000 products on the market across a variety of therapeutic classes (among them cardiovascular, gastrointestinal, and oncology). It also manufactures generic hospital products, including antibiotics, anesthetics, and painkillers. Actavis makes drugs in pill, injectable, suppository, and other forms. Subsidiary Medis distributes its drugs worldwide. Actavis, which was founded in 1956, is controlled by chairman Thor Bjorgolfsson through his investment vehicle Novator. At the company's helm is CEO Sigurdur Oli Olafsson.

Actavis U.S. is the US manufacturing and marketing unit of global generics firm Actavis. The company makes a wide variety of generic equivalents of both prescription and OTC drugs, in a number of forms, including liquids, tablets, creams, and suppositories. Among other consumer and specialty drugs, it makes acetaminophen, ibuprofen, and generic Rogaine. It has also launched generic versions of Pfizer's diabetes drug Glucotrol XL and GlaxoSmithKlein's Coreg tables for hypertension and myocardial infarction. Actavis U.S. has manufacturing facilities in Maryland, New Jersey, and North Carolina, from which it ships its own products and provides contract manufacturing services to third parties.

Apotex Inc. company is Canada's leading generic drugmaker, producing some 300 generic drugs in thousands of varying dosages and formulations. Its product line includes generic equivalents of Merck's Claritin (allergy medication) and Pfizer's Norvasc (hypertension). Apotex markets its drugs throughout Canada and the US, as well as in about 115 other countries in the Asia/Pacific region, Africa, Europe, Latin America, and the Middle East. Apotex company also has a manufacturing agreement with The Harvard Drug Group.

APP Pharmaceuticals, a company that develops, makes, and markets anesthetics and other injectable drugs. Specializing in generics, APP's critical care products segment includes market-leading general anesthetic Diprivan and blood thinner Heparin. Other product segments focus on injectable oncology treatments and drugs that fight ear, heart, respiratory tract, skin, and sinus infections. APP markets through a direct sales force and often sells through group purchasing organizations to customers that include hospitals, long-term care facilities, and clinics in North America. APP Pharmaceuticals, LLC company is a subsidiary of German medical firm Fresenius.

Aspen Pharmacare Holdings is the holding company of Aspen Pharmacare. The company is Africa's largest generic pharmaceutical manufacturer and a major supplier of branded pharmaceutical and healthcare products to southern African and some other international markets. Its products include pain medication, vitamins, cough and cold medicines, laxatives, medicine for indigestion, and aids to help people quit smoking and lose weight. Aspen Pharmacare also led the way in developing the first anti-retroviral medication in South Africa for AIDS treatment. Aspen Pharmacare Holdings Ltd. company has manufacturing facilities in Africa, India, and Latin America.

Caraco Pharmaceutical Laboratories, Ltd. was founded in 1984 and is based in Detroit, Michigan. Caraco Pharmaceutical Laboratories, Ltd. is a subsidiary of Sun Pharmaceutical Industries Limited. Caraco Pharmaceutical Laboratories, Ltd. (Caraco) is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers, throughout the United States and Puerto Rico. During the fiscal year ended March 31, 2009 (fiscal 2009), Caraco received United States Food and Drug Administration (FDA) approval for eight abbreviated new drug applications (ANDAs) relating to three products. It had filed 10 ANDAs relating to nine products with the FDA during fiscal 2009. This brings Caraco’s total number of ANDAs pending approval by the FDA to 29 (including four tentative approvals) relating to 25 products as of March 31, 2009.

Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions.

EastPharma would like to be the place where east meets west. The Turkish pharmaceutical manufacturer operates via two major subsidiaries. Deva Holdings makes branded generics, active pharmaceutical ingredients (API), veterinary products, and consumer hygiene products. Its Saba unit makes generic high-end cardiovascular and pain medications. EastPharma sells about 70 branded generics and a dozen licensed drugs including versions of the blockbuster drugs Viagra, Singulair, and Lamisil. The company operates seven manufacturing plants in and around Istanbul and sell its products in nearly 20 Eastern European countries with an eye toward Western expansion.

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products. The Company’s activity includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. Its technology is applicable to develop delayed, sustained or targeted-release pellets, capsules, tablets, granules and powders. As of March 31, 2009, the Company had two products, Lodrane 24 and Lodrane 24D, being sold commercially, and a pipeline of five additional drug candidates under active development in the therapeutic areas that include pain management, allergy and infection. Of the products under development, ELI-216, a once-a-day, abuse-deterrent oxycodone product, and ELI-154, a once-a-day oxycodone product, are in clinical trials, and Elite has completed pilot studies on two of its other generic product candidates.

Falcon Pharmaceuticals, Ltd. company specializes in making generic equivalents of ophthalmic drugs that treat a range of eye conditions, as well as otic (ear) and nasal ailments. Its lead product, Timolol GFS, is a generic equivalent of Merck's glaucoma treatment Timoptic-XE gel. Falcon Pharmaceuticals company also offers anti-infective, steroid, anti-viral, anti-allergy, and anesthetic pharmaceutical products without the markup typically associated with brand names. Falcon Pharmaceuticals is a subsidiary of eye care products company Alcon.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.